PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
0				Application Number	10/587,277-Conf. #4870	
١N	<b>IFORMATION</b>	I DI	SCLOSURE	Filing Date	July 25, 2006	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	LI Guogiao	
	.,			Art Unit	1616	
	(Use as many sh	eets as	s necessary)	Examiner Name	E. V. Arnold	
Sheet	1	of	2	Attorney Docket Number	13796-00002-US	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA*	US-5,219,865	06-15-1993	Chatterjee et al.		
***************************************	AB*	US-5,270,037	12-14-1993	Bienzle		
	AC*	US-7,670,631	03-02-2010	Mota et al.		
			*******			

		FOREI	GN PATENT	DOCUMENTS		300
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Τ <sup>6</sup>
	ВА	WO-96/40108-A1	12-19-1996	Univ Washington et al.		
	ВВ	WO-02/26226-A1	04-04-2002	Chongqing Kincare Medicinal De et al.		See Abstract

Examiner	Colling	Date	
Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/587,277-Conf. #4870	
11	VFORMATION	I DI	SCLOSURE	Filing Date	July 25, 2006	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	LI Guogiao	
				Art Unit	1616	
ĺ	(Use as many sh	eets as	s necessary)	Examiner Name	E. V. Arnold	
Sheet	2	of	2	Attorney Docket Number	13796-00002-US	

	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of					
Examiner Initials	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	CA	DENIS, M.B. et al., "Efficacy and Safety of Dihydroartemisinin-Piperaquine (Artekin) in Cambodian Children and Adults with Uncomplicated Falciparum Malaria." <i>Clin. Inf. Dis.</i> <b>35(12)</b> , 1469-1476 (2002).				
	СВ	HUANG, J.R. et al., "A study of artemether combined with primaquine in the treatment of falciparum malaria." <i>DATABASE MEDLINE (Online)</i> , U.S. National Library of Medicine, Bethesda, MD, US, 2001, Database Accession No. NLM12572052 (abstract only).				
	CC	CHAWIRA, N. et al., "The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of <i>Plasmodium falciparum in vitro</i> ." <i>Journal of Tropical Medicine and Hygiene</i> <b>90</b> , 1-8 (1987).				
	CD	GIAO, P.T. et al., "CV8, a new combination of dihydroartemisinin, piperaquien, trimethoprim and primaquine, compared with atovaquone-proguanil against falcipraum malaria in Vietnam." <i>Tropical Medicine and International Health</i> <b>9(1)</b> , 109-116 (2004).				
	CE	"Antimalarial Drug Combination Therapy: Report of a WHO Technical Consultation." World Health Organization, 2001, 1-30.				
	CF	JAEGER, A. et al., "Clinical features and management of poisoning due to antimalarial drugs." <i>Med. Toxicol. Adverse Drug Exp.</i> 1987 Jul-Aug; <b>2(4)</b> : 242-73.				
	CG	SRIVASTAVA, P. et al., "Glutathione S transferase activity in malarial parasites." <i>Tropical Medicine and International Health</i> <b>4(4)</b> , January 5, 2002, 251-254.				
	СН	SONG, J. et al., "Clinical Observation of Dihydroartemisinin and Piperaquine in Treating Falciparum Malaria without Complication." <i>National Medical Journal of China</i> <b>83(12)</b> , 6/25/03, 1099-1100 (original article plus English translation).	×			

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.